A randomized controlled trial on the value of misoprostol for the treatment of retained placenta in a low‐resource setting
Rattachement africain : nl, Tanzanie, de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To evaluate the efficacy and safety of misoprostol among patients with retained placenta in a low-resource setting. METHODS: A prospective, multicenter, randomized, double-blind, placebo-controlled trial was carried out in Tanzania between April 2008 and November 2011. It included patients who delivered at a gestational age of 28 weeks or more and had blood loss of 750 mL or less at 30 minutes after delivery. Sublingual misoprostol (800 μg) was compared with placebo as the primary treatment. Power analysis showed that 117 patients would be required to observe a reduction of 40% in the incidence of manual removal of the placenta (MRP; P=0.05, 80% power), the primary outcome. The secondary outcomes were blood loss and number of blood transfusions. RESULTS: Interim analysis after recruitment of 95 patients showed that incidence of MRP, total blood loss, and incidence of blood transfusions were similar in the misoprostol (MRP, 40%; blood loss, 803 mL; blood transfusion, 15%) and placebo (MRP, 33%, blood loss 787 mL, blood transfusion, 23%) groups. The trial was stopped because continuation would not alter the interim conclusion that misoprostol was ineffective. CONCLUSION: Treatment with misoprostol was found to have no clinically significant beneficial effect among women with retained placenta. CLINICAL TRIAL REGISTRATION: Current Controlled Trials ISRCTN16104753.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A randomized controlled trial on the value of misoprostol for the treatment of retained placenta in a low‐resource setting
- Date Crossref
- 19/06/2013
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Erasmus University Rotterdam pays non établi dans la noticeUniversité ou école supérieure
-
Muhimbili University of Health and Allied Sciences Department of Obstetrics and Gynecology Dar es Salaam, Tanzanie (code pays fourni par la source)Université ou école supérieure
-
University of Lübeck Institute for Cancer Epidemiology pays non établi dans la noticeUniversité ou école supérieure
-
Radboud University Nijmegen Department of Obstetrics and Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
Radboud University Medical Center pays non établi dans la noticeOrganisme public
-
Department of Obstetrics and Gynecology pays non établi dans la noticeInstitution
Erasmus University Rotterdam, Department of Obstetrics and Gynecology — Muhimbili University of Health and Allied Sciences (Dar es Salaam, Tanzanie) et Institute for Cancer Epidemiology — University of Lübeck, avec 3 autres affiliations. Pays d’affiliation : Tanzanie.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.